{"id":"clm_98C359CB4FBA","entity":"regeneron-pharmaceuticals","predicate":"revenue","value":"7,863,400,000 United States dollar","value_json":{"fy":2019,"accn":"0001532176-20-000008","form":"10-K","filed":"2020-02-07","concept":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"},"valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 7,863,400,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_98C359CB4FBA, https://asof.is/claim/clm_98C359CB4FBA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm.","url":"https://asof.is/claim/clm_98C359CB4FBA","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9C8093C9515A","supersedes":["clm_002F725B2106"],"first_seen_at":"2026-11-08T17:08:47.537551+00:00","updated_at":"2026-11-08T17:08:55.512322+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000153217620000008/0001532176-20-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2019, filed 2020-02-07"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}